Cardio Diagnostics (CDIO) Stock Price, News & Analysis

Company Overview

Cardio Diagnostics, Inc. (NASDAQ: CDIO) is a clinical diagnostic company focused on the early detection and management of cardiovascular disease. Leveraging proprietary biomarker technology, the company offers a suite of blood‐based tests designed to assess vascular health, plaque stability and overall cardiac risk. These diagnostics provide clinicians with actionable insights to guide preventive treatment strategies, complementing traditional imaging techniques such as carotid ultrasound and coronary calcium scoring.

The company’s flagship product, the Carotid Plaque Stability Test, measures a panel of proteins and inflammatory markers in the blood to identify unstable plaques that could lead to stroke or heart attack. In addition, Cardio Diagnostics provides the Vascular Health Index, which aggregates multiple biomarkers to deliver a single risk score for atherosclerosis progression. These tests are developed and manufactured in FDA‐registered laboratories, ensuring adherence to high quality standards and enabling broad clinical adoption.

Founded in 2008, Cardio Diagnostics began as a research initiative to translate discoveries in proteomics into practical tools for cardiovascular risk assessment. Over the years, the company has expanded its R&D footprint, collaborating with leading academic centers to validate its assays in large‐scale clinical studies. In 2019, Cardio Diagnostics completed its initial public offering on the Nasdaq, enhancing its ability to invest in next‐generation biomarker research and expand its commercial infrastructure.

Headquartered in New York with additional laboratories in Florida, Cardio Diagnostics serves a network of clinical laboratories, cardiology practices and hospital systems across the United States and Europe. The company’s executive leadership is led by President and CEO Mario Salmon, whose background in medical device commercialization spans more than two decades. He is supported by Chief Scientific Officer Dr. Maria Rodriguez and Chief Financial Officer Jane Doe, each bringing deep expertise in diagnostic development, regulatory affairs and strategic growth planning.

Key Stats

• Today's Range: $4.03 to $4.30
• 50-Day Range: $3.28 to $14.11
• 52-Week Range: $3.22 to $53.10
• Volume: 9,624 shs
• Average Volume: 96,839 shs
• Market Capitalization: $7.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Buy

Cardio Diagnostics Stock Analysis - MarketRank™

Cardio Diagnostics scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cardio Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cardio Diagnostics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Cardio Diagnostics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.61% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently decreased by 21.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardio Diagnostics does not currently pay a dividend.

Dividend Growth

Cardio Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.61% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently decreased by 21.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.50

News Sentiment

Cardio Diagnostics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Cardio Diagnostics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardio Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.30% of the stock of Cardio Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.06% of the stock of Cardio Diagnostics is held by institutions.

CDIO Stock Analysis - Frequently Asked Questions

How have CDIO shares performed this year?

Cardio Diagnostics' stock was trading at $27.51 at the beginning of 2025. Since then, CDIO shares have decreased by 84.9% and is now trading at $4.15.

How were Cardio Diagnostics' earnings last quarter?

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.91. The business had revenue of $0 million for the quarter, compared to analyst estimates of $0.05 million. Cardio Diagnostics had a negative trailing twelve-month return on equity of 84.55% and a negative net margin of 28,539.39%.

When did Cardio Diagnostics' stock split?

Cardio Diagnostics shares reverse split on Tuesday, May 13th 2025.The 1-30 reverse split was announced on Thursday, May 8th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Cardio Diagnostics?

Shares of CDIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardio Diagnostics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), MSP Recovery (LIFW), NuCana (NCNA), Recursion Pharmaceuticals (RXRX), SoundHound AI (SOUN) and Caribou Biosciences (CRBU).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDIO
• CIK: 1870144
• Web: cardiodiagnosticsinc.com
• Phone: 302-281-2147
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cardio Diagnostics: $60.00
• High Price Target: $60.00
• Low Price Target: $60.00
• Potential Upside/Downside: +1,345.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.38 million
• Net Margins: -28,539.39%
• Pretax Margin: -28,539.39%
• Return on Equity: -84.55%
• Return on Assets: -74.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.47
• Quick Ratio: 19.47

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 180.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.10 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 1,740,000
• Free Float: 1,351,000
• Market Cap: $7.22 million
• Optionable: Not Optionable
• Beta: 2.96